1.Administración de preparados de inmunoglobulina humana recogidos antes de 1985 (10).
2.Anticuerpos al HLA (a antigenos de los leucocitos Tipo I y II) (7, 10, 13, 43, 46, 48, 49, 53, 63).
3.Anticuerpos anti-células parietales (48).
4.Anticuerpos anticolágenos (encontrados en hombres homosexuales, hemofílicos, africanos de ambos sexos y personas con lepra) (31).
5.Anticuerpos-antihidratos de carbono (13, 19, 52).
6.Anticuerpos antilinfocitos (31, 56).
7.Anticuerpos antimicrosomiales (34).
8.Anticuerpos antimitocondriales (13, 48).
9.Anticuerpos anti-músculos lisos (48).
10.Anticuerpos antinucleares (13, 48, 53).
11.Anticuerpos con una alta afinidad con el polistireno (utilizado en los equipos de pruebas) (3, 40, 62).
12.Anticuerpos del antígeno de leucocitos de las células T (13, 48).
13.Anticuerpos que se dan de forma natural (5, 19).
Artritis reumatoide (36).
14.Cirrosis biliar primaria (13, 43, 48, 53).
15.Colangitis esclerosante primaria (48, 53).
16.Embarazo en mujeres multíparas (13, 36, 43, 53, 58).
17.Enfermedades autoinmunes (10, 29, 40, 43, 44, 49).
18.Especímenes tratados con calor (24, 48, 49, 51, 57).
19.Exposición a vacunas víricas o infección vírica recientes (11).
20.Falsos positivos a otras pruebas, incluyendo el test RPR (rapid plasma reagent) para la sífilis (10, 17, 33, 48, 49).
21.Fiebre Q con hepatitis asociada (61).
22.Globulinas producidas durante gammopatías policlonales (que se observan en grupos de riesgos de SIDA) (10, 13, 48).
23.Gripe (36).
24.Hemofilia (10, 49).
25.Hepatitis (54).
26.Hepatitis alcohólica / enfermedad hepática alcohólica (10, 13, 32, 40, 43, 48, 49, 53).
27.Herpes simple I (27).
28.Herpes simple II (11).
29.Hiperbilirrubinemia (10, 13).
30.Hipergammaglobulemia (niveles altos de anticuerpos) (33, 40).
31.IgM anti-Hbc (48).
32.IgM (anticuerpos) anti-hepatitis A (48).
33.Individuos sanos como resultado de reacciones cruzadas mal entendidas (10).
34.Infección de las vías respiratorias superiores (resfriado o gripe) (11).
35.Infecciones víricas agudas, infecciones víricas del ADN (13, 40, 43, 48, 53, 59).
36.Inmunización pasiva: recepción de gammaglobulina o inmunoglobulina (como profilaxis contra infección que contiene anticuerpos) (4, 13, 18, 22, 26, 42, 43, 60).
37.Insuficiencia renal (13, 23, 48).
38.Insuficiencia renal / Hemodiálisis (10, 16, 41, 49, 56).
39.Leishmaniasis visceral (45).
40.Lepra (2, 25).
41.Lupus eritematoso sistémico (15, 23).
42.Malaria (6, 12).
43.Micobacterium avium (25).
44.Mieloma múltiple (10, 43, 53).
45.Neoplasmas malignos (cánceres) (40).
46.Niveles altos de complejos inmunes circulantes (6, 33).
47.Otros retrovirus (8, 13, 14, 48, 55).
48.Proteínas en el papel de filtro (13).
49.Ribonucleoproteínas humanas normales (13, 48).
50.Sangre «pegajosa» (en africanos) (34, 38, 40).
51.Seropositivos al factor reumatoide, anticuerpos antinucleares (ambos encontrados en la artritis reumatoide y otros autoanticuerpos) (14, 53, 62).
52.Sexo anal receptivo (39, 64).
53.Síndrome de Stevens-Johnson (9, 13, 48).
54.Suero hemolizado (sangre en la que la hemoglobina se separa de las células rojas) (49).
55.Suero lipémico (sangre con niveles altos de grasas o lípidos) (49).
56.Terapia de alfa interferón en pacientes de hemodiálisis (54).
57.Transfusiones sanguíneas, transfusiones sanguíneas múltiples (13, 36, 43, 49, 53, 63).
58.Transplante de órganos (1, 36).
59.Trastornos hematológicos malignos / linfomas (9, 13, 43, 48, 53).
60.Tuberculosis (25).
61.Vacunación de la gripe (3, 11, 13, 20, 30, 43).
62.Vacunación de la hepatitis B (21, 28, 40, 43).
63.Vacunación del tétanos (40).
64.Virus Epstein-Barr (37).
Referencias:
1. Agbalika F., Fercahl F., Garnier J-P, et al. 1992. False-positive antigens related to emergence of a 25-30 protein detected in organ recipients.
2. Andrade V., Avelleira JC., Marques A., et al, 1991. Leprosy as a cause of false-positive results in serological assays for the detection of antibodies to HIV-1. Intl. J. Leprosy. 59:125.
3. Arnold Nl., Slade R.A., Jones M.M., et al, 1994. Donor follow up of influenza vaccine-related multiple viral enzume inmunoassay reactivity. Vox Sanguinis. 67:191.
4. Ascher D., Roberts C. 1993. Determination of the etiology of seroreversals in HIV testing by antibody fingerprinting AIDS. 6:241.
5. Barbacid M., Bolgnesi D., Aaronson S. 1980. Humans have antibodies capable of recognizing oncoviral glucoproteins: Demostration that these antibodies are formed in response to cellular modification of glucoproteins rather than as consequence of exposure to virus. Proc. Nathl. Acad. Sci. 77:1617-1621.
6. Biggar R., Melbye M., Sarin P., et al., 1985. ELISA HTLV retrovirus antibody reactivity associated with malaria and immune complexes in healthy Africans. Lancet. ii:520-543.
7. Blanton M., Balakrishnan K., Dumaswala U., et al, 1987. HLA antibodys in blood donors with reactive sreening tests for antibodys to the immunodeficiency virus. Transfusión. 27 (1):118.
8. Blomberg J., Vincie E., Jonsson C., et al. 1990. Identification of long susthetic peptides AIDS Res. Hum. Retro. 6:1363.
9. Burkhardt U., Metens T., Eggers H. 1987. Comparison of ELA and DuPont HTIV-III ELISA. J. Med. Vir. 23:217.
10. Bylund D., Ziegner U., Hooper D. 1992. Review of testing for human immunodeficiency virus. Clin. Lab. Med. 12:305-333.
11. Challakere K., Rapaport M. 1993. False-positive human inmunodeficiency virus type I ELISA results in low-risk subjects West. J. Med. 159(2):214-215.
12. Charmot G., Simon F. 1990. HIV infection and malaria. Revue du practicien, 40:2141.
13. Cordes R., Ryan M. 1995. Pittalls in HIV testing. Postgraduate Medicine. 98:177.
14. Dock N., Lamberson H., O'Brien T., et al., 1988. Evaluation of atypical human immunodeficiency virus immunoblot reactivity in blood donors. Transfusion 28:142.
15. Esteva M., Blasini A., Ogly D., et al, 1992. False positive results for antibody to HIV in two men with systemic lupus erythematosus. Ann. Rheum. Dis., 51:1071-1073.
16 Fassbinder W., Kuhni P., Neumaver H., et al, 1986. Prevalence of antibodies against LAV/HTLV-III (MIV) in patients with termical renal insufficiency treated with hemodialysis and following renal transplantation. Deutsche Medizinische Wochenschrift 111:1087.
17. Fleming D., Cochi S., Steece R., et al, 1987. Acquired immunodeficiency syndrome in low-incidence areas. JAMA 258(6):785.
18. Gill MJ., Rachlis A., Anand C. 1991. Five cases of erroncously diagnosed HIV infection. Can. Med. Asso. J. 145(12):1593.
19. Healey D., Bolton iW. 1993. Apparent HIV-I glycoprotein reactivity on Western blot in uninfected blood donors. AIDS. 7:655-658.
20. Hisa J., 1993. False-Positive ELISA for human immunodeficiency virus after influenza vaccination HD. 167:989.
21. Isaacman S. 1989. Positive HIV antibody test results after treatment with hepatitis B immune globulin. JAMA, 262:209.
22. Jackson G., Rubens M., Knigge M., et al, 1988. Passive immunoneutralisation of human immunodeficiency virus in patients with advanced AIDS. Lancet. Sept. 17:647.
23. Jindal R., Solomon M., Burrows L. 1993. False positive tests for HIV in a woman with lupus and renal failune. NEJM. 328:1281-1282.
24. Jungkind D., DiRenzo S., Young S. 1986. Effect of using heat inactivated serum with the Abbott human T-cell lymphotropic virus type III (HIV) antibody test. J. Clin. Micro. 23:381.
25. Kashala O., Marlink R., Ilunga M. et al. 1994. Infection with human immunodeficiency virus type I (HIV-I) and human T-cell lymphotropic viruses among leprosy patients and contacts: correlation between HIV-1 cross-reactivity and antibodies to lipoarabionomanna J. Infect. Dis. 169:296-304.
26. Lai-Godman M., McBride J., Howanitz P., et al, 1987. Presence of HTLV-III (HIV) antibodies in immuneserum globulin preparations. Am. J. Clin. Path. 87:635.
27. Langedjk J., Vos W., Doornum G., et al. 1992. Identification of cross-reactive epitopes recognized by HIV-1 fase-positive será. AIDS. 6:1546-1548.
28. Lee D., Eby W., Molinaro G. 1992. HIV false positivity after hepatitis B vaccination. Lancet 339:1060.
29. Leo-Amador G., Ramírez-Rodríguez J., Galván-Villegas E., et al, 1990. Antibodies against human immunodeficiency virus in generalized lupus erythematosus. Salud Pública de México. 32:15.
30. Mackenzie W., Davis J., Peterson D., et al. 1992. Multiple false-positive serologie tests for HIV, HTLV-1 and hepatitis C following influenza vaccination. 1991. JAMA. 268:1015-1017.
31. Mathe G. 1992. Is the AIDS virus responsible for the disease?. Biomed & Pharmacother. 46:1-2.
32. Mendenhall C., Roselle G., Grossman C., et al. 1986. False-positive tests for HTLV-III (HIV) antibodies in alcoholic patients with hepatitis. NEJM. 314:921.
33. Moore J., Cone E., Alexander S. 1986. HTLV-III (HIV) seropositivity in 1971-1972 parenteral drug abusers -a case of false-positives or evidence of viral exposure?. NEJM. 314:1387-1388.
34. Mortimer I., Mortimer J., Parry J. 1985. Which anti-HTLV-III/LAV (HIV) assays for screening and comfirmatory testing?. Lancet. Oct 10. p. 837.
35. Ncale T., Dagger J., Fong R., et al. 1985. False-positive anti-HTLV-III (HIV) serology. New Zealand Med. J. October 23.
36. Ng V. 1991. Serological diagnosis with recombinant peptides/proteins. Clin. Chem. 37:1667-1668.
37. Ozanne G., Fauvel M. 1988. Perfomance and reliability of five commercial enzyme.linked immunosorbent assay kits in screening for anti-human immunodeficiency virus antibody in high-risk subjects. J. Clin. Micro, 26:1496.
38. Papadopulos-Eleopulos E. 1988. Reappraisal of AIDS -Is the oxidation induced by the risk factors the primary cause?. Med. Hypo. 25:151.
39. Papadopulos-Eleopulos E., Turner V. and Papadimitriou J. 1993. Is a positive Western blot proof of HIV infection?. Bio/technology. June 11:696/707.
40. Pearlman ES., Ballas SK. 1994. False-positive human immunodeficiency virus screening test related to rabies vaccination. Arch. Pathol. Lab. Med. 118-805.
41. Peternan T., Lang G., Mikos N., et Hemodialysis/renal failure. 1986. JAMA. 255:2324.
42. Piszkewiez D. 1987. HTLV-III (HIV) antibodies after immune globulin. JAMA. 257:316.
43. Profitt MR., Yen-Lieberman B. 1993. Laboratory diagnosis of human immunodeficiency virus infection. Inf. Dis. Clin. North. Am. 7:203.
44. Ranki A., Kurti P., Reipponen S., et al. 1992. Antibodies to retroviral proteins in autoimmune connective tissue disease. Arthritis and Rheumatism. 35:1483.
45. Ribero T., Bries C., Moreira E., et al. 1993. Serologie validation of HIV infection in a tropical area. JAIDS. 6:319.
46. Savers M., Beatty P., Hansen J. 1986. HLA antibodies as a cause of false-positive reactions in screening enzyme immunoassays for antibodies to human T-lymphotropic virus type III (HIV). Transfusion. 26(1):114.
47. Sayre KR., Dodd RY., Tegtmeier G., et al, 1996. False-positive human immunodeficiency virus type 1 Western blot tests in non infected blood donodrs. Transfusion. 36:45.
48. Schleupner CJ. Detection of HIV-1 infection. In: (Mandell GI., Douglas RG., Bennet JE., eds.). Principles and Practice of Infectious Diseases, 3rd ed. New York: Churchill Livingstone. 1990:1092.
49. Schochetman G., George J. 1992. Serologic tests for the detection of human immunodeficiency virus infection. In AIDS Testing Methodology and Management Issues, Springer-Verlag. New York.
50. Simonsen L., Buffington J., Shapiro C., et al. 1995. Multiple false reactions in viral antibody screening assays after influenza vaccination. Am. J. Epidem. 141:1089.
51. Smith D., Dewhurst S., Shepherd S., et al. 1987. False-positive enzyme-linked immunosorbent assay reactions for antibody to human immunodeficiency virus in a population of midwestern patients with congenital bleeding disorders. Transfusion. 127:112.
52. Snyder H., Fleissner E. 1980. Specifity of human antibodies to oncovirus glucoproteins; Recognition of antigen by natural antibodies directed against carbohydrate structures. Proc. Natl. Acad. Sci. 77:1622-1626.
53. Steckelberg JM., Cockerill F. 1988. Serologie testing for human immunodeficiency virus antibodies. Mayo Clin. Proc. 63:373.
54. Sungar C., Akpolat T., Ozkuyumen C., et al. Alpha interferon therapy in hemodialysis patients. Nephron. 67:251.
55. Tribe D., Reed D., Lindell P., et al. 1988. Antibodies reactive with human immunodeficiency virus gag-coated antigens (gag reactive only) are a major cause of enzyme-linked immunosorbent assay reactivity in a bood donor population. J. Clin. Micro. April:641.
56. Ujhelyi E., Fust G., Illei G., et al. 1989. Different types of false positive anti-HIV reactions in patients on hemodialysis. Immun. Let. 22:35-40.
57. Van Beers D., Duys M. Maes M., et al. Heat inactivation of serum may interfere with tests for antibodies to LAV/HTLV-III (HIV). J. Vir. Meth. 12:329.
58. Voevodin A. 1992. HIV screening in Russia. Lancet. 339:1548.
59. Weber B., Moshtaghi-Borogeni M., Brunner M., et al. 1995. Evaluation of the reliability of six current anti-HIV-1/HIV-2 enzyme immunoassays. J. Vir. Meth. 55:97.
60. Wood C., Williams A., McNamara J., et al. 1986. Antibody against the human immunodeficiency virus in commercial intravenous gammaglobulin preparations. Ann. Int. Med. 105:536.
61. Yale S., Degroen P., Tooson J., et al. 1994. Unusual aspects of acute Q fever-associated hepatitis. Mayo Clin. Proc. 69:769.
62. Yoshida T., Matsui T., Kobayashi M., et al. 1987. Evaluation of passive particle agglutination test for antibody to human immunodeficiency virus. J. Clin. Micro. Aug:1433.
63. Yu S., Fong C., Landry M., et al. 1989. A false positive HIV antibody reaction due to transfusion-induced HLA-DR4 sensitization. NEJM. 320:1495.
64. National Institute of Justice. AIDS Bulletin. Oct. 1988.
Artículo publicado en el número 47 de la revista «Medicina Holística».
Edita: Asociación de Medicinas Complementarias
Vía: http://free-news.org/htm/SIDA-03.htm
y textos antropocríticos
